Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 7, 2017, Pages 460.e21-460.e28

  Hammerich, Kai H ^a   Donahue, Timothy F ^b   Rosner, Inger L ^c,d,e   Cullen, Jennifer ^d,e   Kuo, Huai Ching ^d   Hurwitz, Lauren ^d   Chen, Yongmei ^d   Bernstein, Melanie ^b   Coleman, Jonathan ^b   Danila, Daniel C ^b   Metwalli, Adam R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d Center for Prostate Disease Research (CPDR)   (United States)

^e Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Biomarker; Cancer specific death; Castrate resistant prostate cancer; Prostate; Prostate cancer; Prostate cancer progression

Indexed keywords

ALKALINE PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER CENTER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; COHORT ANALYSIS; ENZYME KINETICS; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE SURGERY; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; BONE TUMOR; METABOLISM; MORTALITY; SECONDARY; SURVIVAL ANALYSIS;

ALKALINE PHOSPHATASE; BONE NEOPLASMS; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85017364632     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2017.02.001     Document Type: Article

References (23)

1. D'Amico, A.V., Cote, K., Loffredo, M., Renshaw, A.A., Schultz, D., Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2002), 4567–4573.
2. Ryan, C.J., et al. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer 110 (2007), 81–86.
3. Norgaard, M., Jensen, AØ, Jacobsen, J.B., Cetin, K., Fryzek, J.P., Sørensen, H.T., Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184 (2010), 162–167, 10.1016/j.juro.2010.03.034 [Epub 2010 May 16].
4. Sathiakumar, N., et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 14 (2011), 177–183.
5. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-49s.
6. Koo, K.C., Park, S.U., Kim, K.H., Rha, K.H., Hong, S.J., Yang, S.C., et al. Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. Prostate Int 3 (2015), 10–15.
7. Smith, M.R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M.C., Bilhartz, D.L., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23 (2005), 2918–2925.
8. Cook, R.J., Coleman, R., Brown, J., Lipton, A., Major, P., Hei, Y.J., et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12 (2006), 3361–3367.
9. Lein, M., Wirth, M., Miller, K., Eickenberg, H.U., Weissbach, L., Schmidt, K., et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52 (2007), 1381–1387.
10. Sonpavde, G., Pond, G.R., Berry, W.R., de Wit, R., Armstrong, A.J., Eisenberger, M.A., et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 30 (2012), 607–613.
11. Metwalli, A.R., Rosner, I.L., Cullen, J., Chen, Y., Brand, T., Brassell, S.A., et al. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. Urol Oncol 32 (2014), 761–768.
12. Schulman, K.L., Kohles, J., Economic burden of metastatic bone disease in the U.S. Cancer 109 (2007), 2334–2342.
13. Barlev, A., Song, X., Ivanov, B., Setty, V., Chung, K., Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 16 (2010), 693–702.
14. Hussain, M., Tangen, C.M., Higano, C., Schelhammer, P.F., Faulkner, J., Crawford, E.D., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006), 3984–3990.
15. Pound, C.R., Partin, A.W., Eisenberger, M.A., Chan, D.W., Pearson, J.D., Walsh, P.C., Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 281 (1999), 1591–1597.
16. Freedland, S.J., Humphreys, E.B., Mangold, L.A., Eisenberger, M., Dorey, F.J., Walsh, P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Am Med Assoc 294 (2005), 433–439.
17. Wilt, T.J., Brawer, M.K., Jones, K.M., Barry, M.J., Aronson, W.J., Fox, S., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367 (2012), 203–213.
18. Scher, H.I., Morris, M.J., Basch, E., Heller, G., End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 29 (2011), 3695–3704.
19. Hong, S.Y., Cho, D.S., Kim, S.I., Ahn, H.S., Kim, S.J., Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer. Korean J Urol 53 (2012), 607–613.
20. Chi, K.N., Kheoh, T., Ryan, C.J., Molina, A., Bellmunt, J., Vogelzang, N.J., et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol 27 (2016), 454–460.
21. Mikah, P., Krabbe, L.M., Eminaga, O., Herrmann, E., Papavassilis, P., Hinkelammert, R., et al. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer, 16, 2016, 214.
22. Rao SR, Snaith AE, Kratschmer P. Tumour-derived alkaline phosphatase promotes epithelial-mesenchymal transition (EMT) and cell survival in bone metastatic prostate cancer: a novel role in prostate cancer metastasis. Fourth Joint Meeting of ECTS and IBMS 2015 The Netherlands, Rotterdam 25–28 April 2015 ECTS-IBMS Abstracts (2015). p. 101.
23. US Census Bureau Population Estimates. Vintage 2012: Downloadable Data Files. https://www.census.gov/popest/data/historical/2010s/vintage_2012/datasets.html.